<DOC>
	<DOCNO>NCT01878227</DOCNO>
	<brief_summary>The purpose study compare lipid lowering effect clinical safety natural hypolipidemic compound , coenzyme A capsule market drug , fenofibrate , Chinese patient moderate dyslipidemia .</brief_summary>
	<brief_title>Comparison Coenzyme A Fenofibrate Safety Efficacy On Patients With Hyperlipidemia</brief_title>
	<detailed_description>Although lower cholesterol low-density lipoprotein-cholesterol ( LDL-C ) mainstay medical therapy cardiovascular event prevention , evidence clinical trial support role elevate triglyceride ( TG ) low high-density lipoprotein cholesterol ( HDL-C ) concentration residual cardiovascular risk statin treatment . Fenofibrate commonly use agent control hypertriglyceridemia monotherapy combine statin , lower TG raise HDL-C multifaceted mechanism PPARα activation . However , safety coadministration statin fenofibrate great concern , especially drug-induced hepatotoxicity combine use . Coenzyme A ( CoA ) function acyl group carrier assist transfer fatty acid cytoplasm mitochondrion . It also involve oxidation catabolism fatty acid . Animal study prove lipid-lowering effect . In previous multicenter study conduct 2008 , find oral CoA 400U/d effectively lower serum TG level hypertriglyceridemia patient without increase adverse effect compare placebo . So , present study perform investigate lipid-lowing effect safety CoA capsule compare fenofibrate .</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hyperlipoproteinemias</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>TG 2.3～6.5mmol/l 1875 year age TC &gt; 7.0 mmol/l ; Body Mass Index &gt; 30 kg/m2 drug induce secondary hypercholesterolemia ( dibenzothiazine , contraceptive agent adrenal cortex hormone ) pregnancy acute coronary syndrome , acute myocardial infarction undergone revascularization procedure within 6 month acute liver disease hepatic dysfunction , determine level alanine aminotransferase ( ALT ) aspartate aminotransferase level ( AST ) 3fold upper normal limit nephrotic syndrome serum creatinine ( Cr ) ( ≥179 µmol/L ) creatine •phosphokinase ( CK ) 3fold upper normal limit primary hypothyroidism psychiatric patient poorly control hypertension , indicate Systolic Blood Pressure &gt; 180 mmHg Diastolic Blood Pressure &gt; 110 mmHg Type I diabetes mellitus（DM） , poorly control Type II DM ( BS &gt; 11.0 mmol/L ) Type II DM LDLC &gt; 2.6 mmol/L . use immunosuppressive drug , prohibit medication lipidlowing drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>